Human Ameloblastoma: Pathogenesis, Clinical Presentation, Management, and Future Perspectives: A brief Review Ameloblastoma: A brief Review

Article Sidebar

PDF
Published: Jun 29, 2024
DOI: https://doi.org/10.58564/jmob.101
Keywords:
Ameloblastoma, odontogenic tumor, clinical presentation, management, molecular markers

Main Article Content

Naseer A Nasir
College of Dentistry / Al- Iraqia University/Iraq/ Baghdad
https://orcid.org/0009-0005-7616-3740
Karima Akool Al Salihi
College of dentistry/ Al-Iraqia University
https://orcid.org/0000-0002-5698-2678
Zeena Tariq Abdulhadi
College of Dentistry / Al- Iraqia University/Iraq/ Baghdad
https://orcid.org/0000-0002-3724-3677

Abstract

Ameloblastoma, a benign yet locally aggressive odontogenic tumor poses significant diagnostic and therapeutic challenges. This review intends to present a synopsis of human ameloblastoma's different aspects, including its pathogenesis, clinical presentation, diagnostic modalities, treatment strategies, and emerging research avenues from previously reported articles. By analyzing existing literature and clinical insights, this manuscript improved the understanding and facilitated optimal management of ameloblastoma,  the complex pathology.

Article Details

How to Cite
Nasir , N. A., Al Salihi , K. A., & Abdulhadi, Z. T. (2024). Human Ameloblastoma: Pathogenesis, Clinical Presentation, Management, and Future Perspectives: A brief Review : Ameloblastoma: A brief Review . Journal of Medical and Oral Biosciences ( JMOB), 1(1). https://doi.org/10.58564/jmob.101
Issue
Vol. 1 No. 1 (2024): Vol.1.(No.1).2024
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.

Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 

Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/

https://creativecommons.org/licenses/by-sa/4.0/      

References

1. Al-Salihi KA and Ling Yoke Li and Ahmad Azlina. P53 gene mutation and protein expression in ameloblastomas. Braz J Oral Sci. 2006;5(17): 1034-1040.

2. Kshirsagar K, Patil P, Munde A, Gadbail A, Sonune S, Chaudhary M. Role of immunomarkers in the pathogenesis and malignant transformation of ameloblastoma: A systematic review. J Oral Maxillofac Pathol. 2020;24(2):233-240. doi:10.4103/jomfp.JOMFP_230_20.

3. Vered M, Shohat I, Buchner A, Dayan D. Myofibroblasts in stroma of odontogenic cysts and tumors can contribute to variations in the biological behavior of lesions. Oral Oncol. 2005;41(10):1028-33. doi:10.1016/j.oraloncology.2005.06.005.

4. Hanemann JAC, Oliveira DT, Garcia NG, et al. CD4+/CD8+ ratio in ameloblastomas and its correlation with clinicopathological parameters. J Oral Pathol Med. 2021;50(1):54-59. doi:10.1111/jop.13095.

5. Braimah RO, Anyanechi CE, Okoye C, et al. Ameloblastoma: A 10-year experience and a review of the literature in a Nigerian tertiary hospital. Niger J Clin Pract. 2018;21(10):1327-1333. doi:10.4103/njcp.njcp_138_18.

6. Iordanidis S, Makos C, Dimitrakopoulos J, Kariki H, Perdikaris A, Kalyvas D. Ameloblastoma: Clinicopathological analysis of 47 cases. Eur J Cancer B Oral Oncol. 1996;32B(5):322-325. doi:10.1016/0964-1955(96)00005-7.

7. Rosli TI, Halim AS, Ramli R. Immunohistochemical Expression of p53 in Ameloblastoma. Sains Malaysiana. 2011;40(3):221-226. [DOI: 10.1007/s10284-021-04234-x]

8. Kishore M, Panat SR, Shenoy RK. Metastasizing ameloblastoma: A clinico-pathological insight. Contemp Clin Dent. 2016;7(2):251-254. doi:10.4103/0976-237X.183063.

9. Tiwari A, Garg A, Gandhi S, Mishra A, Tandon P, Singh A. Ameloblastoma: Current etiopathological concepts and management. Oral Maxillofac Surg. 2021;25(3):277-287. doi:10.1007/s10006-021-00966-1.

10. Ricciardiello F, Caradonna L, Ventura G, et al. A case of ameloblastoma with a rare anatomical location: A comprehensive review of the literature. Case Rep Med. 2021;2021:6635395. doi:10.1155/2021/6635395.

11. Kumar A, Kumar V, Singh AK, Sharma A, Yadav A. Ameloblastoma: A comprehensive review and recent updates. J Oral Biosci. 2021;63:258-266. doi:10.1016/j.job.2021.06.006.

12. Ng KH, Siar CH. Ameloblastomas in Malaysians: a histopathological survey using modified WHO diagnostic criteria. J Nihon Univ Sch Dent. 1997;39(2):97-104. [PMID: 9246934]

13. Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO. Ameloblastoma: current etiopathological concepts and management. Oral Diseases. 2018;24:307–316 doi:10.1111/odi.12646

14. Ong ST, Siar CH. Expression of P53 Protein and Ki-67 Antigen in Ameloblastomas. Journal of Oral Pathology & Medicine. 1998;27(8):376-382. [DOI: 10.1111/j.1600-0714.1998.tb02038.x]

15. Al-Salihi K A, Ihsan Abdullah, Ling Yoke Li. Clinico-radiologic features of four cases of Ameloblastoma. Brazilian Journal of Oral Sciences. 2018; 17:e18028. http://dx.doi.org/10.20396/bjos.v17i0.8651903

16. Ghandhi D, Ayoub AF, Pogrel MA, MacDonald G, Brocklebank LM, Moos KF. Ameloblastoma: A surgeon's dilemma. J Oral Maxillofac Surg. 2006;64(7):1010-1014. doi:10.1016/j.joms.2006.02.022.

17. Kallarakkal TG, Ibrahim WN, Wastie ML, Zain RB. P53 expression in ameloblastoma and keratocystic odontogenic tumor: comparison of two antibodies. Biotech Histochem. 2014;89(8):588-592. [DOI: 10.3109/10520295.2014.927335]